Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized, double-blind, placebo-controlled trial of BI 425809 in schizophrenia
2016-000285-28Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2016
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of iclepertin in schizophrenia (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change in composite MCCB score at 12 weeks. Started Apr 2016; status: completed.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2016-000285-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000285-28.